Last reviewed · How we verify
NCT07480720
Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease
trial in Graves Disease in 100 participants. Currently enrolling.
1 April 2026
Quick facts
| Lead sponsor | Elazıg Fethi Sekin Sehir Hastanesi |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 March 2026 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 May 2026 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Graves Disease — all drugs for Graves Disease →
- Graves Ophthalmopathy — all drugs for Graves Ophthalmopathy →
Sponsor
Elazıg Fethi Sekin Sehir Hastanesi — full company profile →
Who can join
18 and older, any sex, with Graves Disease or Graves Ophthalmopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in patients with Graves disease. Medical records of patients diagnosed with Graves disease and healthy control subjects evaluated at Elazığ Fethi Sekin City Hospital between August 2018 and January 2026 will be reviewed. Optical coherence tomography (OCT) measurements, including macular thickness and peripapillary retinal nerve fiber layer (RNFL) thickness, will be analyzed. Laboratory parameters such as complete blood count-derived inflammatory indices, C-reactive protein, thyroid function tests, and thyroid autoantibodies will also be recorded. The study will compare neuroretinal parameters between healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy, and will investigate potential associations between systemic inflammation, thyroid autoimmunity, and neuroretinal structural changes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07480720
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Graves Disease
Currently open trials in the same condition.
- NCT07305818 — NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease · Phase 1 · recruiting
- NCT07286656 — A Study of GensSci098 in Subjects With Graves' Disease · Phase 1 · recruiting
- NCT07129642 — Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease · EARLY_PHASE1 · recruiting
- NCT07369063 — Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease · Phase 2 · recruiting
- NCT07059507 — Prevalence and Predictors of Incidental Thyroid Carcinoma in Patients With Graves' Disease Undergoing Thyroidectomy. · recruiting
Other Elazıg Fethi Sekin Sehir Hastanesi trials
Trials by the same sponsor.
- NCT07435896 — Impact of Information and Participation on Decision Time for Tracheostomy or PEG in ICU Families · not yet recruiting
- NCT07437443 — Burnout, Secondary Traumatic Stress and Inflammatory Biomarkers in ICU Healthcare Workers · not yet recruiting
- NCT07434362 — Serum Endocan, Alarin, and Galanin-Like Peptide Levels in Diabetic Retinopathy · NA · completed
- NCT07415928 — Inhibin B/FSH Ratio as a Predictor of Testicular Pathology in NOA · completed
- NCT07326644 — Effect of Gestational Weight Gain on Spinal Anesthesia in Elective Cesarean Delivery · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07480720 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Elazıg Fethi Sekin Sehir Hastanesi
- Last refreshed: 18 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07480720.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing